A(2A) blockade enhances anti-metastatic immune responses

The specific targeting of tumor-elicited immunosuppression is a promising strategy for the treatment of cancer. We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A(2A)/A(2B) adenosine receptors significantly reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Beavis, Paul A, Milenkovski, Nicole, Stagg, John, Smyth, Mark J, Darcy, Phillip K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926871/
https://www.ncbi.nlm.nih.gov/pubmed/24575377
http://dx.doi.org/10.4161/onci.26705
Descripción
Sumario:The specific targeting of tumor-elicited immunosuppression is a promising strategy for the treatment of cancer. We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A(2A)/A(2B) adenosine receptors significantly reduced the metastatic potential of CD73(+) breast carcinomas and melanomas via both immunological and non-immunological mechanisms.

Ejemplares similares